These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 22251095)

  • 1. Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition.
    Rossios C; To Y; Osoata G; Ito M; Barnes PJ; Ito K
    Br J Pharmacol; 2012 Oct; 167(4):775-86. PubMed ID: 22251095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.
    Kobayashi Y; Wada H; Rossios C; Takagi D; Charron C; Barnes PJ; Ito K
    Br J Pharmacol; 2013 Jul; 169(5):1024-34. PubMed ID: 23758162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-δ.
    Mercado N; To Y; Ito K; Barnes PJ
    J Pharmacol Exp Ther; 2011 May; 337(2):465-70. PubMed ID: 21300705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial.
    Dalby C; Polanowski T; Larsson T; Borgström L; Edsbäcker S; Harrison TW
    Respir Res; 2009 Oct; 10(1):104. PubMed ID: 19878590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.
    To Y; Ito K; Kizawa Y; Failla M; Ito M; Kusama T; Elliott WM; Hogg JC; Adcock IM; Barnes PJ
    Am J Respir Crit Care Med; 2010 Oct; 182(7):897-904. PubMed ID: 20224070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.
    Lee DK; Jackson CM; Currie GP; Cockburn WJ; Lipworth BJ
    Br J Clin Pharmacol; 2003 Nov; 56(5):494-500. PubMed ID: 14651722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroids plus long-acting β2-agonists prevent double-stranded RNA-induced upregulation of B7-H1 on airway epithelium.
    Kan-O K; Matsumoto K; Inoue H; Fukuyama S; Asai Y; Watanabe W; Kurokawa M; Araya J; Kuwano K; Nakanishi Y
    Int Arch Allergy Immunol; 2013; 160(1):27-36. PubMed ID: 22948082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased corticosteroid sensitivity by a long acting β2 agonist formoterol via β2 adrenoceptor independent protein phosphatase 2A activation.
    Kobayashi Y; Mercado N; Miller-Larsson A; Barnes PJ; Ito K
    Pulm Pharmacol Ther; 2012 Jun; 25(3):201-7. PubMed ID: 22401993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cryptotanshinone Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ in Chronic Obstructive Pulmonary Disease.
    Xie T; Huang R; Deng D; Tang P; Fu Y; Zheng Y; Wan Y
    Int J Chron Obstruct Pulmon Dis; 2023; 18():797-809. PubMed ID: 37180749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease.
    Nannini L; Lasserson TJ; Poole P
    Cochrane Database Syst Rev; 2003; (4):CD003794. PubMed ID: 14583994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formoterol and salmeterol induce a similar degree of β2-adrenoceptor tolerance in human small airways but via different mechanisms.
    Cooper PR; Kurten RC; Zhang J; Nicholls DJ; Dainty IA; Panettieri RA
    Br J Pharmacol; 2011 Jun; 163(3):521-32. PubMed ID: 21306583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.
    Frois C; Wu EQ; Ray S; Colice GL
    Clin Ther; 2009 Dec; 31(12):2779-803. PubMed ID: 20110019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Hozawa M
    Pulm Pharmacol Ther; 2014 Apr; 27(2):190-6. PubMed ID: 24388868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting β2 agonists and corticosteroids restore the reduction of histone deacetylase activity and inhibit H2O2-induced mediator release from alveolar macrophages.
    Perng DW; Su KC; Chou KT; Wu YC; Chen CS; Hsiao YH; Tseng CM; Chen YH; Hsueh TY; Lee YC
    Pulm Pharmacol Ther; 2012 Aug; 25(4):312-8. PubMed ID: 22546485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic inhibition by beta(2)-agonists and corticosteroids on tumor necrosis factor-alpha-induced interleukin-8 release from cultured human airway smooth-muscle cells.
    Pang L; Knox AJ
    Am J Respir Cell Mol Biol; 2000 Jul; 23(1):79-85. PubMed ID: 10873156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effects of two inhaled corticosteroid/long-acting β₂-agonist combinations in the treatment of asthma.
    Yatera K; Yamasaki K; Nishida C; Noguchi S; Oda K; Akata K; Nagata S; Kawanami Y; Kawanami T; Ishimoto H; Mukae H
    J Asthma; 2014 Sep; 51(7):762-8. PubMed ID: 24654703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.
    Spencer S; Evans DJ; Karner C; Cates CJ
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007033. PubMed ID: 21975759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-δ/Akt pathway and increasing GR expression.
    Sun XJ; Li ZH; Zhang Y; Zhou G; Zhang JQ; Deng JM; Bai J; Liu GN; Li MH; MacNee W; Zhong XN; He ZY
    Am J Physiol Lung Cell Mol Physiol; 2015 Jul; 309(2):L139-46. PubMed ID: 25957293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD.
    Haque R; Hakim A; Moodley T; Torrego A; Essilfie-Quaye S; Jazrawi E; Johnson M; Barnes PJ; Adcock IM; Usmani OS
    J Allergy Clin Immunol; 2013 Nov; 132(5):1166-73. PubMed ID: 24070494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.